Compositions and methods for predicting response to napi2b-targeted therapy
AssigneeMersana Therapeutics, Inc.
InventorsRebecca MOSHER, Laura L. POLING, Donald A. BERGSTROM
Life of this patent
Estimating the term…
Abstract
This disclosure provides reagents and methods of predicting the responsiveness of a patient to NaPi2b-targeted antibody-drug conjugates (e.g., NaPi2b-targeted antibody-polymer-drug conjugates).
Claims28
A method of predicting the responsiveness of a NaPi2b expressing cancer patient to treatment with a NaPi2b-targeted antibody drug conjugate comprising:
- a. measuring the expression level of NaPi2b in a tumor sample obtained from the patient by contacting the tumor sample with an anti-NaPi2b antibody;
- b. predicting that the patient with be responsive to treatment when:
- the expression level of NaPi2b in the tumor sample is higher than a predetermined quantitative or a semi quantitative score cut-off score determined by the H-score method, light microscopy or image analysis.
(canceled)
(canceled)
A method of treating a cancer in a subject with a NaPi2b-targeted antibody drug conjugate comprising:
- a. measuring the expression level of NaPi2b in a tumor sample obtained from the patient by contacting the tumor sample with an anti-NaPi2b antibody;
- b. predicting that the patient with be responsive to treatment when:
- the expression level of NaPi2b in the tumor sample is higher than a predetermined quantitative or a semi quantitative score cut-off score determined by the H-score method, light microscopy or image analysis;
- and
- c. administering the NaPi2b-targeted antibody drug conjugate to a subject predicted to be responsive.
-11. (canceled)
-15. (canceled)
-19. (canceled)
A method of subtyping a non-small cell lung carcinoma as adenocarcinoma comprising:
- detecting whether NaPi2b is present in a non-small cell lung carcinoma sample by contacting the sample with an anti-NaPi2b antibody and detecting binding between NaPi2b and the antibody;
- and subtyping a non-small cell lung carcinoma as adenocarcinoma when the presence of NaPi2b is detected in the sample immunohistochemically.
(canceled)
-29. (canceled)
A chimeric antibody comprising:
- a variable heavy chain complementarity determining region 1 (CDRH1) comprising the amino acid sequence GYTFTGYNIH (SEQ ID NO:
- 3), a variable heavy chain complementarity determining region 2 (CDRH2) comprising the amino acid sequence AIYPGNGDTSYKQKFRG (SEQ ID NO:
- 4), a variable heavy chain complementarity determining region 3 (CDRH3) comprising the amino acid sequence GETARATFAY (SEQ ID NO:
- 5), a variable light chain complementarity determining region 1 (CDRL1) comprising the amino acid sequence SASQDIGNFLN (SEQ ID NO:
- 6), a variable light chain complementarity determining region 2 (CDRL2) comprising the amino acid sequence YTSSLYS (SEQ ID NO:
- 7), a variable light chain complementarity determining region 3 (CDRL3) comprising the amino acid sequence QQYSKLPLT (SEQ ID NO:
- 8).
-36. (canceled)
A method of treating papillary thyroid cancer, papillary renal cancer, salivary duct adenocarcinoma, endometrial cancer or cholangiocarcinoma comprising administering to the subject NaPi2b-targeted antibody drug conjugate in an amount sufficient to alleviate the symptom of the cancer.
Dependencies are inferred from the claim text.